Murphy PK, Sellers ME, Bonds SH, Scott S. The SEER Program’s longstanding commitment to making cancer resources available. JNCI Monogr. 2024;2024:118–22.
Chen Y, Deng J, Liu Y, Wang H, Zhao S, He Y, et al. Analysis of metastases in non-small cell lung cancer patients with epidermal growth factor receptor mutation. Ann Transl Med. 2021;9:206.
Google Scholar
Huang Y, Hong W, Wei X. The molecular mechanisms and therapeutic strategies of EMT in tumor progression and metastasis. J Hematol Oncol. 2022;15:129.
Google Scholar
Leonetti A, Sharma S, Minari R, Perego P, Giovannetti E, Tiseo M. Resistance mechanisms to osimertinib in EGFR-mutated non-small cell lung cancer. Br J Cancer. 2019;121:725–37.
Google Scholar
Dudás J, Ladányi A, Ingruber J, Steinbichler TB, Riechelmann H. Epithelial to mesenchymal transition: a mechanism that fuels cancer radio/chemoresistance. Cells. 2020;9:428.
Google Scholar
Saitoh M. Transcriptional regulation of EMT transcription factors in cancer. Semin Cancer Biol. 2023;97:21–29.
Google Scholar
Yu X, He T, Tong Z, Liao L, Huang S, Fakhouri WD, et al. Molecular mechanisms of TWIST1-regulated transcription in EMT and cancer metastasis. EMBO Rep. 2023;24:e56902.
Google Scholar
Nam M-W, Kim C-W, Choi K-C. Epithelial-mesenchymal transition-inducing factors involved in the progression of lung cancers. Biomol Ther. 2022;30:213–20.
Google Scholar
Pallier K, Cessot A, Côté JF, Just PA, Cazes A, Fabre E, et al. TWIST1, a new determinant of epithelial to mesenchymal transition in EGFR-mutated lung adenocarcinoma. PLoS ONE. 2012;7:e29954.
Google Scholar
Kang E, Seo J, Yoon H, Cho S. The post-translational regulation of epithelial–mesenchymal transition-inducing transcription factors in cancer metastasis. Int J Mol Sci. 2021;22:3591.
Google Scholar
Ruvolo PP. The broken “Off” switch in cancer signaling: PP2A as a regulator of tumorigenesis, drug resistance, and immune surveillance. BBA Clin. 2016;6:87–99.
Google Scholar
Schuhmacher D, Sontag J-M, Sontag E. Protein phosphatase 2A: more than a passenger in the regulation of epithelial cell–cell junctions. Front Cell Dev Biol. 2019;7:30.
Google Scholar
Sablina AA, Hector M, Colpaert N, Hahn WC. Identification of PP2A complexes and pathways involved in cell transformation. Cancer Res. 2010;70:10474–84.
Google Scholar
Janghorban M, Langer EM, Wang X, Zachman D, Daniel CJ, Hooper J, et al. The tumor suppressor phosphatase PP2A-B56α regulates stemness and promotes the initiation of malignancies in a novel murine model. PLoS ONE. 2017;12:e0188910.
Google Scholar
Mannava S, Omilian AR, Wawrzyniak JA, Fink EE, Zhuang D, Miecznikowski JC, et al. PP2A-B56α controls oncogene-induced senescence in normal and tumor human melanocytic cells. Oncogene. 2012;31:1484–92.
Google Scholar
Tinsley SL, Chianis E, Shelley RA, Mall GK, Dhiman A, Baral G, et al. KRAS-mediated upregulation of CIP2A promotes suppression of PP2A-B56α to initiate pancreatic cancer development. Oncogene. 2024;43:3673–87.
Google Scholar
Raoof S, Mulford IJ, Frisco-Cabanos H, Nangia V, Timonina D, Labrot E, et al. Targeting FGFR overcomes EMT-mediated resistance in EGFR mutant non-small cell lung cancer. Oncogene. 2019;38:6399–413.
Google Scholar
Crystal AS, Shaw AT, Sequist LV, Friboulet L, Niederst MJ, Lockerman EL, et al. Patient-derived models of acquired resistance can identify effective drug combinations for cancer. Science. 2014;346:1480–6.
Google Scholar
Benton A, Moriarty NM, Terwilliger E, Liu B, Murphy A, Maluvac H, et al. miR-497 target gene regulatory network in angiosarcoma. Mol Cancer Res. 2024;22:879–90.
Google Scholar
Grecco GG, Huang JY, Muñoz B, Doud EH, Hines CD, Gao Y, et al. Sex-dependent synaptic remodeling of the somatosensory cortex in mice with prenatal methadone exposure. Adv Drug Alcohol Res. 2022;2:10400.
Google Scholar
McCracken NA, Liu H, Runnebohm AM, Wijeratne H, Wijeratne AB, Staschke KA, et al. Obtaining functional proteomics insights from thermal proteome profiling through optimized melt shift calculation and statistical analysis with InflectSSP. Mol Cell Proteom: MCP. 2023;22:100630.
Google Scholar
Orsburn BC. Proteome Discoverer—a community-enhanced data processing suite for protein informatics. Proteomes. 2021;9:15.
Google Scholar
Zhou Y, Zhou B, Pache L, Chang M, Khodabakhshi AH, Tanaseichuk O, et al. Metascape provides a biologist-oriented resource for the analysis of systems-level datasets. Nat Commun. 2019;10:1523.
Google Scholar
Győrffy B. Transcriptome-level discovery of survival-associated biomarkers and therapy targets in non-small-cell lung cancer. Br J Pharmacol. 2024;181:362–74.
Google Scholar
Arnold HK, Sears RC. A tumor suppressor role for PP2A-B56α through negative regulation of c-Myc and other key oncoproteins. Cancer Metastasis Rev. 2008;27:147–58.
Google Scholar
Allen-Petersen BL, Risom T, Feng Z, Wang Z, Jenny ZP, Thoma MC, et al. Activation of PP2A and inhibition of mTOR synergistically reduce MYC signaling and decrease tumor growth in pancreatic ductal adenocarcinoma. Cancer Res. 2018;79:209–19.
Google Scholar
Farrington CC, Yuan E, Mazhar S, Izadmehr S, Hurst L, Allen-Petersen BL, et al. Protein phosphatase 2A activation as a therapeutic strategy for managing MYC-driven cancers. J Biol Chem. 2019;295:757–70.
Google Scholar
Arnold HK, Sears RC. Protein phosphatase 2A regulatory subunit B56α associates with c-Myc and negatively regulates c-Myc accumulation. Mol Cell Biol. 2006;26:2832–44.
Google Scholar
Tsherniak A, Vazquez F, Montgomery PG, Weir BA, Kryukov G, Cowley GS, et al. Defining a cancer dependency map. Cell. 2017;170:564–76.e16.
Google Scholar
Wang C-Y, Chao TT, Chang FY, Chen YL, Tsai YT, Lin HI, et al. CIP2A mediates erlotinib-induced apoptosis in non-small cell lung cancer cells without EGFR mutation. Lung Cancer. 2014;85:152–60.
Google Scholar
Khanna A, Okkeri J, Bilgen T, Tiirikka T, Vihinen M, Visakorpi T, et al. ETS1 mediates MEK1/2-dependent overexpression of cancerous inhibitor of protein phosphatase 2A (CIP2A) in human cancer cells. PLoS ONE. 2011;6:e17979.
Google Scholar
Han H, Cho JW, Lee S, Yun A, Kim H, Bae D, et al. TRRUST v2: an expanded reference database of human and mouse transcriptional regulatory interactions. Nucleic Acids Res. 2018;46:D380–6.
Google Scholar
Sánchez-Tilló E, Pedrosa L, Vila I, Chen Y, Győrffy B, Sánchez-Moral L, et al. The EMT factor ZEB1 paradoxically inhibits EMT in BRAF-mutant carcinomas. JCI Insight. 2023;8:e164629.
Google Scholar
Schuhwerk H, Kleemann J, Gupta P, van Roey R, Armstark I, Kreileder M, et al. The EMT transcription factor ZEB1 governs a fitness-promoting but vulnerable DNA replication stress response. Cell Rep. 2022;41:111819.
Google Scholar
Bader GD, Hogue CW. An automated method for finding molecular complexes in large protein interaction networks. BMC Bioinform. 2003;4:2.
Aakula A, Sharma M, Tabaro F, Nätkin R, Kamila J, Honkanen H, et al. RAS and PP2A activities converge on epigenetic gene regulation. Life Sci Alliance. 2023;6:e202301928.
Google Scholar
Kim IK, Lee YS, Kim HS, Dong SM, Park JS, Yoon DS. Specific protein 1(SP1) regulates the epithelial-mesenchymal transition via lysyl oxidase-like 2(LOXL2) in pancreatic ductal adenocarcinoma. Sci Rep. 2019;9:5933.
Google Scholar
Zhang H, Zhang G, Zhang J, Xiao M, Cui S, Wu S, et al. Transcription factor SP1 and oncoprotein PPP1R13L regulate nicotine-induced epithelial-mesenchymal transition in lung adenocarcinoma via a feedback loop. Biochem Pharmacol. 2022;206:115344.
Google Scholar
Yin J, Hu W, Fu W, Dai L, Jiang Z, Zhong S, et al. HGF/MET-regulated epithelial-mesenchymal transitions and metastasis by FOSL2 in non-small cell lung cancer. OncoTargets Ther. 2019;12:9227–37.
Google Scholar
Wang X, Lu H, Urvalek AM, Li T, Yu L, Lamar J, et al. KLF8 promotes human breast cancer cell invasion and metastasis by transcriptional activation of MMP9. Oncogene. 2011;30:1901–11.
Google Scholar
Jing P, Xie N, Zhao N, Zhu X, Li P, Gao G, et al. miR-24-3p/KLF8 signaling axis contributes to LUAD metastasis by regulating EMT. J Immunol Res. 2020;2020:4036047.
Google Scholar
Wang X, Zheng M, Liu G, Xia W, McKeown-Longo PJ, Hung MC, et al. Krüppel-Like factor 8 induces epithelial to mesenchymal transition and epithelial cell invasion. Cancer Res. 2007;67:7184–93.
Google Scholar
Meškytė EM, Keskas S, Ciribilli Y. MYC as a multifaceted regulator of tumor microenvironment leading to metastasis. Int J Mol Sci. 2020;21:7710.
Google Scholar
Yin S, Cheryan VT, Xu L, Rishi AK, Reddy KB. Myc mediates cancer stem-like cells and EMT changes in triple-negative breast cancer cells. PLoS ONE. 2017;12:e0183578.
Google Scholar
Cho KB, Cho MK, Lee WY, Kang KW. Overexpression of c-myc induces epithelial-mesenchymal transition in mammary epithelial cells. Cancer Lett. 2010;293:230–9.
Google Scholar
Taniguchi H, Yamada T, Wang R, Tanimura K, Adachi Y, Nishiyama A, et al. AXL confers intrinsic resistance to osimertinib and advances the emergence of tolerant cells. Nat Commun. 2019;10:259.
Google Scholar
Sun X, Chen H, You S, Tian Z, Wang Z, Liu F, et al. AXL upregulates c-Myc expression through AKT and ERK signaling pathways in breast cancers. Mol Clin Oncol. 2023;18:22.
Google Scholar
Tinsley SL, Allen-Petersen BL. PP2A and cancer epigenetics: a therapeutic opportunity waiting to happen. Nar Cancer. 2022;4:zcac002.
Google Scholar
Hertz EPT, Kruse T, Davey NE, López-Méndez B, Sigurðsson JO, Montoya G, et al. A conserved motif provides binding specificity to the PP2A-B56 phosphatase. Mol Cell. 2016;63:686–95.
Google Scholar
Casalino L, Talotta F, Matino I, Verde P. FRA-1 as a regulator of EMT and metastasis in breast cancer. Int J Mol Sci. 2023;24:8307.
Google Scholar
Kim N, Jung J. Exploring the role of AKAP12 in cancer progression and therapeutic implication. Drug Targets Ther. 2025;4:59–66.
Zhao Y, Liu MJ, Zhang L, Yang Q, Sun QH, Guo JR, et al. High mobility group A1 (HMGA1) promotes the tumorigenesis of colorectal cancer by increasing lipid synthesis. Nat Commun. 2024;15:9909.
Google Scholar
Jolly MK, Ware KE, Gilja S, Somarelli JA, Levine H. EMT and MET: necessary or permissive for metastasis? Mol Oncol. 2017;11:755–69.
Google Scholar
Bankhead P, Loughrey MB, Fernández JA, Dombrowski Y, McArt DG, Dunne PD, et al. QuPath: open source software for digital pathology image analysis. Sci Rep. 2017;7:16878.
Google Scholar
Haanen TJ, O’Connor CM, Narla G. Biased holoenzyme assembly of protein phosphatase 2A (PP2A): From cancer to small molecules. J Biol Chem. 2022;298:102656.
Google Scholar
Zhang L, Zhou H, Li X, Vartuli RL, Rowse M, Xing Y, et al. Eya3 partners with PP2A to induce c-Myc stabilization and tumor progression. Nat Commun. 2018;9:1047.
Google Scholar
Tohmé R, Izadmehr S, Gandhe S, Tabaro G, Vallabhaneni S, Thomas A, et al. Direct activation of PP2A for the treatment of tyrosine kinase inhibitor–resistant lung adenocarcinoma. JCI Insight. 2019;4:e125693.
Google Scholar
Kim HY, Jackson TR, Davidson LA. On the role of mechanics in driving mesenchymal-to-epithelial transitions. Semin Cell Dev Biol. 2017;67:113–22.
Google Scholar
Aghdassi A, Sendler M, Guenther A, Mayerle J, Behn CO, Heidecke CD, et al. Recruitment of histone deacetylases HDAC1 and HDAC2 by the transcriptional repressor ZEB1 downregulates E-cadherin expression in pancreatic cancer. Gut. 2012;61:439–48.
Google Scholar
Manshouri R, Coyaud E, Kundu ST, Peng DH, Stratton SA, Alton K, et al. ZEB1/NuRD complex suppresses TBC1D2b to stimulate E-cadherin internalization and promote metastasis in lung cancer. Nat Commun. 2019;10:5125.
Google Scholar
Ramalingam SS, Vansteenkiste J, Planchard D, Cho BC, Gray JE, Ohe Y, et al. Overall survival with osimertinib in untreated, EGFR-mutated advanced NSCLC. N Engl J Med. 2019;382:41–50.
Google Scholar
Soria J-C, Ohe Y, Vansteenkiste J, Reungwetwattana T, Chewaskulyong B, Lee KH, et al. Osimertinib in untreated EGFR-mutated advanced non–small-cell lung cancer. N Engl J Med. 2017;378:113–25.
Google Scholar
Sequist LV, Waltman BA, Dias-Santagata D, Digumarthy S, Turke AB, Fidias P, et al. Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors. Sci Transl Med. 2011;3:75ra26.
Google Scholar
Zatzman M, Quintanal-Villalonga A, Salehi S, Ceglia N, Lee JJ, Pupo AN, et al. Complementary modes of resistance to EGFR TKI in lung adenocarcinoma through MAPK activation and cellular plasticity. Preprint at https://doi.org/10.1101/2025.05.07.652714.
Verusingam ND, Chen YC, Lin HF, Liu CY, Lee MC, Lu KH, et al. Generation of osimertinib-resistant cells from epidermal growth factor receptor L858R/T790M mutant non-small cell lung carcinoma cell line. J Chin Méd Assoc. 2020;84:248–54.
